InvestorsHub Logo
Followers 3186
Posts 208744
Boards Moderated 2
Alias Born 02/04/2004

Re: wimuskyfisherman post# 34744

Tuesday, 05/08/2018 9:45:47 AM

Tuesday, May 08, 2018 9:45:47 AM

Post# of 38634
Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER

Toronto, Ontario May 8, 2018 – Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has commenced its Category 2 and 3 human abuse liability studies for the Company’s Oxycodone ER product candidate to support its abuse-deterrent label claims for the intranasal route of administration.

“This is a very important step towards resubmission of our NDA for Oxycodone ER” commented Dr. Isa Odidi, CEO of Intellipharmaceutics. “We have continued to work with the FDA since receipt of the Complete Response Letter late last year and we refined our studies based on their recommendations. We have a very clear plan to complete the remaining work and feel confident that we will meet our goal of resubmission later this year.”

The Company’s new drug application (“NDA”) for an abuse-deterrent version of Oxycodone ER (oxycodone hydrochloride extended release formulation) was accepted for filing by the U.S. Food and Drug Administration (“FDA”) in February 2017. The submission was supported by Category 1 abuse-deterrent studies (to support intravenous abuse deterrent label claim) and pivotal pharmacokinetic studies that demonstrated that the product is bioequivalent to OxyContin® (oxycodone hydrochloride extended release) and can be administered with or without a meal (i.e., no food effect). A joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA held in July 2017 expressed a desire to review additional data for Oxycodone ER that may be obtained from human abuse potential studies for the oral and intranasal routes of administration.

The Company has now begun the abuse liability studies for the intranasal route of abuse. The planned studies to support abuse-deterrent label claims for the oral route of abuse are scheduled to commence within the next few weeks. Both studies are expected to take several months to complete. The intranasal abuse liability study is being conducted by Altasciences Clinical Research based in Montreal.

There can be no assurance that Intellipharmaceutics will not be required to conduct further studies for Oxycodone ER, that the FDA will approve any of the Company's requested abuse-deterrent label claims or that the FDA will ultimately approve the NDA for the sale of Oxycodone ER in the U.S. market, or that it will ever be successfully commercialized.


Never buy or sell based on my posts! My posts are just my opinion!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y